Loading...

Biovica strengthens management team

Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.

2019-12-10T20:09:39+00:00 December 6th, 2019 08:00|News|

Biovica’s DiviTum – Strong prognostic marker in operable breast cancer

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world´s largest scientific congress focusing on breast cancer.

2019-12-10T20:09:39+00:00 November 20th, 2019 08:20|News|

Biovica’s DiviTum validated as a dynamic biomarker in metastatic breast cancer in collaboration with Institut Curie, Paris

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced that clinical data – demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for metastatic breast cancer patients treated with endocrine therapy and palbociclib – will be presented at the San Antonio Breast Cancer Symposium, December 10-14, 2019, the world´s largest scientific congress focusing on breast cancer.

2019-12-10T20:09:39+00:00 November 20th, 2019 08:00|News|

Biovica strengthens with new R&D Director

Uppsala, November 15, 2019. Biovica, active in cancer diagnostics, today announced that Otti Bengtsson Gref has been appointed new R&D Director and will be part of the management team. She most recently comes from the role as R&D Director at Cavidi.

2019-12-10T20:09:39+00:00 November 15th, 2019 08:00|Regulatory|

Biovica ISO 13485:2016 certificate renewal

Uppsala, Sweden, October 25, 2019. Biovica, active in cancer diagnostics, announced today that the company has renewed their ISO 13485:2016 certificate for three years following an extensive renewal audit with the company’s accreditation body. The certificate covers the development, manufacturing and sale of DiviTum®. 

2019-12-10T20:09:39+00:00 October 25th, 2019 11:28|News|

Biovica will present at the Biomarkers & Precision Medicine Congress in San Diego

The 4th Annual Biomarkers & Precision Medicine Congress will be arranged October 8-9 in San Diego, USA. With increased focus on precision medicine follows a need to translate scientific progress into patient benefits through personalized healthcare. The focus of the Biomarker Congress is the discovery and clinical development of biomarkers and Biovica has been invited to present DiviTum®. The congress includes presentations, case studies and panel discussions with participants from global pharmaceutical and biotech companies, as well as academic institutions.

2019-12-10T20:09:39+00:00 October 3rd, 2019 08:45|News|

DiviTum® Included in New U.S. Cancer Study

Biovica and the SWOG Cancer Research Network have entered into an agreement to study the clinical benefit of DiviTum® using patient blood samples from SWOG 0226, a clinical trial that showed that women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs.

2019-12-10T20:09:39+00:00 September 18th, 2019 08:00|News|

Biovica invites to telephone conference/audiocast

Uppsala, Sweden, September 18, 2019. Biovica invites investors, analysts and the media to a presentation where Anders Rylander, CEO, and Mattias Bergqvist, Clinical Development Director, comments on today’s announcement. The presentation will be held on 19 September 2019 at 10:00 CET and can be followed via telephone conference or audiocast.

2019-12-10T20:09:39+00:00 September 18th, 2019 08:00|News|

New scientific publication focuses on DiviTum® and highlights the need for biomarkers of CDK4/6 inhibitors

A new publication in the scientific journal Frontiers in Oncology, authored by researchers at the Prato hospital in Italy, emphasize the need to find and utilize biomarkers to identify early treatment resistance and predict the likelihood of successful treatment to a new group of drugs, CDK 4/6 inhibitors. The article focuses on biomarkers and highlights DiviTum® as a technology with great potential, strong rationale and already documented pre-clinical and clinical data to evaluate CDK4/6 inhibitor efficacy.

2019-12-10T20:09:39+00:00 September 17th, 2019 08:00|News|